<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Bolt Biotherapeutics — News on 6ix</title>
<link>https://6ix.com/company/bolt-biotherapeutics</link>
<description>Latest news and press releases for Bolt Biotherapeutics on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 12 Mar 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/bolt-biotherapeutics" rel="self" type="application/rss+xml" />
<item>
<title>Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Thu, 12 Mar 2026 20:05:00 GMT</pubDate>
<description>First-in-class immune-stimulating antibody conjugate BDC-4182 in Phase 1 dose escalation study, initial clinical data expected in 3Q 2026 Cash balance of $31.8 million as of December 31, 2025 anticipated to fund key milestones into 2027 REDWOOD CITY, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the fourth quarter and full</description>
</item>
<item>
<title>Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-reports-third-quarter-210500112</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-reports-third-quarter-210500112</guid>
<pubDate>Wed, 12 Nov 2025 21:05:00 GMT</pubDate>
<description>Initial clinical data for BDC-4182 Phase 1 dose escalation study expected in 3Q 2026 Cash balance of $38.8 million as of September 30, 2025 anticipated to fund key milestones into 2027 REDWOOD CITY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. “In</description>
</item>
<item>
<title>Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027</title>
<link>https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-provides-bdc-4182-200500809</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-provides-bdc-4182-200500809</guid>
<pubDate>Wed, 01 Oct 2025 20:05:00 GMT</pubDate>
<description>Initial clinical data for BDC-4182 Phase 1 dose escalation study now expected in 3Q 2026Company is implementing a 50% workforce reduction to extend cash runway into 2027 REDWOOD CITY, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced an update on the ongoing Phase 1 dose escalation study of BDC-4182, a next-generation Boltbody™ ISAC clinical candid</description>
</item>
<item>
<title>Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-reports-second-quarter-200500505</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-reports-second-quarter-200500505</guid>
<pubDate>Thu, 14 Aug 2025 20:05:00 GMT</pubDate>
<description>Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. “In the sec</description>
</item>
<item>
<title>Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-reports-first-quarter-200500505</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-reports-first-quarter-200500505</guid>
<pubDate>Mon, 12 May 2025 20:05:00 GMT</pubDate>
<description>BDC-4182 Phase 1 dose-escalation study now open for enrollmentBDC-3042 Phase 1 dose-escalation data presented at AACR 2025 demonstrated a favorable safety profile, dose-dependent biological activity, and monotherapy anti-tumor activity Bolt is running a partnering process to advance development of BDC-3042Cash balance of $58.0 million as of March 31, 2025 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT)</description>
</item>
<item>
<title>Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates</title>
<link>https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-host-kol-conference-120000946</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-host-kol-conference-120000946</guid>
<pubDate>Thu, 08 May 2025 12:00:00 GMT</pubDate>
<description>Conference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced it will host a key opinion leader (KOL) conference call and webcast featuring Ecaterina Dumbrava, M.D., associate professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center an</description>
</item>
<item>
<title>Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025</title>
<link>https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-presents-preclinical-results-200500854</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-presents-preclinical-results-200500854</guid>
<pubDate>Wed, 30 Apr 2025 20:05:00 GMT</pubDate>
<description>CEA-targeted ISAC elicits complete responses in mice and is well-tolerated in NHPs PD-L1 ISAC directly activates and reprograms PD-L1-expressing myeloid cells in the TME to drive complete responses and immunological memory REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced preclinical results from its next-generation Boltbody™ ISACs t</description>
</item>
<item>
<title>Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025</title>
<link>https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-presents-results-phase-170000479</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-presents-results-phase-170000479</guid>
<pubDate>Fri, 25 Apr 2025 17:00:00 GMT</pubDate>
<description>BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events BDC-3042 showed biological activity, with clear dose-dependent increases in proinflammatory cytokines and chemokines BDC-3042 showed signs of anti-tumor activity, including an unconfirmed partial response, stable disease ≥ 12 weeks in 3/3 non-small cell lung cancer patients and in 2/3 patients at the highest dose Bolt is running a partnering process to advance development of</description>
</item>
<item>
<title>Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025</title>
<link>https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-present-data-phase-203000726</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-present-data-phase-203000726</guid>
<pubDate>Tue, 25 Mar 2025 20:30:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced it will present data from the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancers at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois. BDC-3042 is a proprietary agonist antibody th</description>
</item>
<item>
<title>Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-reports-fourth-quarter-202000688</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-reports-fourth-quarter-202000688</guid>
<pubDate>Mon, 24 Mar 2025 20:20:00 GMT</pubDate>
<description>BDC-4182 on track to start a clinical trial in gastric cancer in second quarter 2025BDC-3042 Phase 1 clinical trial fully enrolled the highest dose cohort with no dose-limiting toxicities (DLTs), results will be reported in second quarter 2025Cash balance of $70.2 million as of December 31, 2024 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing nov</description>
</item>
<item>
<title>Bolt Biotherapeutics to Participate in Upcoming March Conferences</title>
<link>https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-participate-upcoming-march-210500007</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-participate-upcoming-march-210500007</guid>
<pubDate>Tue, 25 Feb 2025 21:05:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in March: TD Cowen 45th Annual Health Care ConferenceCompany presentation on Tuesday, March 4, 2025 at 3:10 p.m. EST (1:10 p.m. PST) Leerink Partners Global Healthcare ConferenceParticipating in 1x1 meetings on Monday, March</description>
</item>
<item>
<title>Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.</title>
<link>https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-inc-provides-update-on-global-cancer-immunotherapy-co-development-with-toray-industries-inc-1</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-inc-provides-update-on-global-cancer-immunotherapy-co-development-with-toray-industries-inc-1</guid>
<pubDate>Tue, 11 Feb 2025 05:00:00 GMT</pubDate>
<description>-- Targeting Unmet Needs for Treating Solid Tumors-- REDWOOD CITY, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc., announced today that</description>
</item>
<item>
<title>Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-reports-third-quarter-2024-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-reports-third-quarter-2024-financial-results-and-provides-business-update</guid>
<pubDate>Tue, 12 Nov 2024 05:00:00 GMT</pubDate>
<description>Advanced to the highest dose level in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancersPresented updated preclinical</description>
</item>
<item>
<title>Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting</title>
<link>https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-presents-updated-preclinical-data-for-bdc-4182-and-key-learnings-from-phase-1-dose-escalation-trial-of-bdc-1001-at-sitc-39th-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-presents-updated-preclinical-data-for-bdc-4182-and-key-learnings-from-phase-1-dose-escalation-trial-of-bdc-1001-at-sitc-39th-annual-meeting</guid>
<pubDate>Thu, 07 Nov 2024 05:00:00 GMT</pubDate>
<description>BDC-4182 demonstrated compelling anti-tumor activity and an acceptable safety profile in preclinical studies BDC-4182 outperformed cytotoxic claudin 18.2 ADCs</description>
</item>
<item>
<title>Bolt Biotherapeutics Announces Changes to its Board of Directors</title>
<link>https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-announces-changes-to-its-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-announces-changes-to-its-board-of-directors</guid>
<pubDate>Wed, 04 Sep 2024 04:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel</description>
</item>
<item>
<title>Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-reports-second-quarter-2024-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-reports-second-quarter-2024-financial-results-and-provides-business-update</guid>
<pubDate>Tue, 13 Aug 2024 04:00:00 GMT</pubDate>
<description>Advanced to Cohort 6 in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancersAbstract accepted for BDC-4182, a claudin</description>
</item>
<item>
<title>Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team</title>
<link>https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-reports-first-quarter-2024-results-announces-strategic-pipeline-prioritization-and-changes-to-leadership-team</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-reports-first-quarter-2024-results-announces-strategic-pipeline-prioritization-and-changes-to-leadership-team</guid>
<pubDate>Tue, 14 May 2024 04:00:00 GMT</pubDate>
<description>Refocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-generation Boltbody™ ISAC platform including new clinical candidate BDC- 4182</description>
</item>
<item>
<title>Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-business-update</guid>
<pubDate>Thu, 21 Mar 2024 04:00:00 GMT</pubDate>
<description>– BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward 2024 milestones– BDC-3042 Phase 1 study successfully</description>
</item>
<item>
<title>Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®</title>
<link>https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-enrolls-first-patient-in-phase-2-clinical-study-evaluating-bdc-1001-in-patients-with-her2-positive-breast-cancer-previously-treated-with-enhertur</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-enrolls-first-patient-in-phase-2-clinical-study-evaluating-bdc-1001-in-patients-with-her2-positive-breast-cancer-previously-treated-with-enhertur</guid>
<pubDate>Tue, 05 Dec 2023 05:00:00 GMT</pubDate>
<description>BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and</description>
</item>
<item>
<title>Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-reports-third-quarter-2023-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-biotherapeutics/news/bolt-biotherapeutics-reports-third-quarter-2023-financial-results-and-provides-business-update</guid>
<pubDate>Thu, 09 Nov 2023 05:00:00 GMT</pubDate>
<description>BDC-1001 program advances in multiple Phase 2 clinical studies in patients with HER2-positive colorectal, gastric, endometrial, and metastatic breast cancer,</description>
</item>
</channel>
</rss>